Kornimate/medical-research-clean huggingface dataset:
efficacy of electroacupuncture compared with transcutaneous electric nerve stimulation for functional constipation

Conditions: Functional Constipation

Summary: the objective of this trial is to compare the efficacy of electroacupuncture versus transcutaneous electric nerve stimulation for functional constipation

both electroacupuncture(ea) therapy and transcutaneous electric nerve stimulation(tens) are safe and effective for functional constipation, but no head to head comparing trial was conducted. methods：102 participants with functional constipation will be recruited and randomly allocated into the ea group and the tens group.participants in both groups will receive ea or tens treatment at tianshu(st 25), fujie(sp 14) and shangju xu(st 37) 3 times a week for 8 weeks.

Eligibility criteria:
inclusion criteria: 1. conforming to the criteria for the diagnosis of functional constipation in rome iii standard; 2. aged of 18 to 75 years; 3. no medication for constipation has been used for at least 2 weeks before treatment. except for emergency treatment, it has not received acupuncture treatment for constipation in the past 3 months, and has not participated in other ongoing clinical research. exclusion criteria: 1. constipation caused by irritable bowel syndrome and organically or medicated; secondary to endocrine, metabolic, neurogenic, or surgical constipation; 2. subjects with serious heart, liver, kidney damage or cognitive impairment, aphasia, mental disorders, or the inability to cooperate with the examination and treatment. 3. pregnant or lactation patients; 4. subjects with abdominal aortic aneurysm, abnormal enlargement of liver and spleen and so on. 5. subjects with coagulation dysfunction or anticoagulants such as warfarin and heparin have been used all the time. 6. subjects installed with the cardiac pacemaker.

Keywords: acupuncture functional constipation transcutaneous electric nerve stimulation randomized controlled trial
a study to assess molecular changes in adult participants with moderate to severe hidradenitis suppurativa or with moderate to severe atopic dermatitis receiving subcutaneous injections of lutikizumab

Conditions: Hidradenitis Suppurativa; Atopic Dermatitis

Summary: hidradenitis suppurativa (hs) and atopic dermatitis (ad) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. the purpose of this study is to assess molecular changes in adult participants with moderate to severe hs or with moderate to severe ad. lutikizumab (abt-981) is an investigational drug being developed for the treatment of hs and ad. this study will consist of 2 sub-studies: sub-study 1 moderate to severe hidradenitis suppurativa and sub-study 2 moderate to severe atopic dermatitis. approximate 60 participants will be enrolled in the study at approximately 2 sites in the us. in sub-study 1 hs participants will receive subcutaneous (sc) injections of lutikizumab for up to week 15 with a 70-day follow-up period. in sub-study 2 ad, participants will receive subcutaneous (sc) injections of lutikizumab for up to week 14 with a 70-day follow-up period. the study duration for sub-studies 1 and 2 is expected to last up to 30 weeks. participants in sub-study 1 (hs) who complete week 16 and showed a therapeutic benefit to lutikizumab, as confirmed by the investigator, will have the option to enter an open-label long-term extension (lte) to continue to receive lutikizumab for up to an additional 140 weeks, followed by a 70-day follow-up period. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.


Eligibility criteria:
inclusion criteria: * sub-study 1 hidradenitis suppurativa (hs): * participants with a diagnosis of moderate-to-severe hs for at least 6 months prior to baseline as determined by the investigator * participants naïve to biologic treatment for hs or must have a prior inadequate response or loss of response to anti-tnf therapy for hs (\>= 12 weeks of therapy). * sub-study 2 atopic dermatitis (ad): * participants with a diagnosis of moderate-to-severe ad with onset of symptoms at least 1 year prior to baseline. * participants naïve to biologic treatment for ad or must have a prior inadequate response or loss of response to dupilumab for ad (defined as \>= 8 weeks of therapy with dupilumab). exclusion criteria: * history of any malignancy within the last 5 years except for successfully treated nonmelanoma skin cancer (nmsc) or localized carcinoma in situ of the cervix. * history of active skin disease (other than hs for sub-study 1 or ad for sub-study 2) that could interfere with the assessment of hs (for sub-study 1) or ad (for sub-study 2), including skin infections (e.g., bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the baseline.

Keywords: hidradenitis suppurativa (hs) atopic dermatitis (ad) lutikizumab abt-981
electrically evoked compound action potentials human observation medtronic algorithm comparison study

Conditions: Chronic Pain

Summary: this is a prospective, multi-center, randomized, single-blind, cross-over, non-significant risk ide research study to evaluate the in-clinic performance of a closed-loop algorithm in spinal cord stimulation (scs) therapy with an ens device.


Eligibility criteria:
inclusion criteria: * 22 years of age or older * candidate for or undergoing medtronic scs device trial for labeled indication - candidate for or undergoing a medtronic scs device trial for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo medtronic scs trialing to treat the patient's chronic pain. this decision is to be made prior to discussing with the patient whether to enroll in the study * willing and able to provide signed and dated informed consent * capable of comprehending and consenting in english * willing and able to comply with all study procedures and visits * clear, measurable ecap ecaps - if during set up of the in-clinic testing, the subject does not have a clear, measurable ecap (\>10uv amplitude obtained consistently and repeatably) they will not move forward with testing or randomization and will be considered a screen failure. exclusion criteria: * implanted electrical cardiac devices (e.g., pacemaker, defibrillator) * currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the medtronic study manager or designee) * pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study * has untreated major psychiatric comorbidity, as determined by the investigator or designee * trialed with a permanent implant lead and extension ("buried lead trial") * if subject is classified as vulnerable or requires a legally authorized representative (lar)
a magnetic resonance imaging study and arthroscopic biopsy substudy in subjects with active rheumatoid arthritis receiving vx-509, an oral jak3 inhibitor

Conditions: Rheumatoid Arthritis

Summary: the current study is designed to evaluate the safety and efficacy, including mri imaging, across a range of vx-509 doses in subjects with active rheumatoid arthritis (ra) who have had an inadequate response to disease-modifying antirheumatic drugs (dmards).

vx-509 is an oral, selective janus kinase 3 (jak3) inhibitor being developed by vertex. in autoimmune diseases, jak3 is an essential component of the immune signaling cascade. this cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of rheumatoid arthritis (ra), irreversible damage to cartilage and bones. selective inhibition of jak3 offers a new disease modifying approach to the treatment of ra, and a broad range of other autoimmune diseases.

Eligibility criteria:
inclusion criteria: * male and female subjects 18 to 65 years of age (inclusive) * diagnosis of ra * swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints * seropositivity based on either a positive rheumatoid factor or anti cyclic citrullinated peptide antibody at screening -or- known erosive disease based on previous x-ray report or erosions detected on screening hand and foot x-ray * baseline crp level or westergren erythrocyte sedimentation rate ≥1.2 × upper limit of normal * receiving stable therapy with 1 of the following dmards: methotrexate, sulfasalazine, leflunomide, anti-malarial drug, or penicillamine * palpable 2+ synovitis of the wrist or ≥2 mcps in the mri-designated hand exclusion criteria: * history or presence of a clinically significant medical disorder other than ra that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. * inflammatory, rheumatological disorders other than ra, where arthritis may be a prominent feature * planned surgery during the study * history of alcohol or drug abuse, or excessive alcohol consumption * history of tuberculosis (tb) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-tb treatment. * pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant
retrospective non-interventional analysis of opportunistic infections in immunocompromised and frail patients

Conditions: Hematologic Disease; Neoplams; Transplantation; Immunologic Deficiency Syndromes; Critical Illness

Summary: the analysis of a cohort of consecutive non-selected patients from the strasbourg university hospital, and therefore representative of the real life, will allow better identifying the risk factors for these infections (by comparison with a cohort of patient with similar conditions of immunosuppression and no infection) and improving the diagnosis and therapeutic management. the primary objective is to identify prognosis factors affecting survival in patients with opportunistic infections


Eligibility criteria:
inclusion criteria: * non selected consecutive immunocompromised or frail patients with an opportunistic infection * hospitalized in any of the department of the university hospital of strasbourg * for epidemiological study, patients with similar immunodepression of frail condition and no opportunistic infection exclusion criteria: - opposition of the patient to use his personal data
possible pharmacological effect of quercetin in the management of hyperuricemia - results from real-life clinical studies

Conditions: Hyperuricemia

Summary: quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. as a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

in the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. these participants visited nutritional clinics in italy during the coronavirus disease (covid-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against covid-19 infection. the supplements, either quercetin or probiotic streptococcus salivarius k12 (blis k12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Eligibility criteria:
inclusion criteria: * healthy adults * bmi between 18.5 and 29.9 kg/m² * non-smoker * consumtion of less than 3 units of alcohol per day exclusion criteria: * - plasma uric acid concentrations above 7 mg/dl * diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones
effects of the covid-19 health emergency on biopsychosocial health

Conditions: Activities; Mental Health Issue; Life Style

Summary: there is a critical need to determine the impact of the covid-19 emergency on the comprehensive well-being of people as they are living through the emergency and sequelae of the emergency period. the research team is requesting national institutes of health funding with the goal to investigate rural vs. urban living people's response to the crisis and its impact using mixed methods research.

the state of new mexico and the entire nation have entered an unprecedented health emergency created by the covid-19 virus; affecting the lives of all people, many of whom were significantly unprepared for the disruptions the emergency created in daily life. rural residents are at increased risk from effects of the emergency due to numerous disadvantages as compared to urban living people (i.e. critical care access, food insecurity, social isolation). very little is known about how people are living through a national emergency event affecting all people of the nation. therefore, a significant gap in knowledge exists: 1. how are rural-living vs. urban-living people responding physically and mentally to the crisis? 2. what strategies of resilience are employed by people living in rural vs. urban counties? 3. what are perceptions of access to critical supplies and services in urban vs. rural counties; 4. how is the availability and use of technology used for news, reliable information, and communication? and 5. use of time: what alterations in daily life self-care, care of others, commerce, and valued routines in urban vs. rural counties are occurring?

Eligibility criteria:
inclusion criteria: * urban and rural living residents of new mexico, any gender, gender identity, any ethnic origin, any health status (healthy, chronic, disabled), and adult age from 18-85 exclusion criteria: * non-new mexico residents, adults unable to give consent due to cognition or incarceration status

Keywords: quality of life rural community covid-19
postoperative analgesic effect of esketamine

Conditions: Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor; Analgesia

Summary: the aim of this study was to determine whether the addition of esketamine to morphine would improve postoperative analgesia after caesarean section. parturients who planned for a caesarean delivery using combined spinal-epidural anaesthesia with a request for postoperative anaesthesia were randomly divided into four groups (a, b, c and d). when the surgery was completed, the parturients in groups a, b, c and d were administered 2 mg morphine, 0.25mg/kg of esketamine, 0.25mg/kg of esketamine plus 2 mg morphine sulfate and 0.25mg/kg of esketamine plus 1 mg morphine through the epidural catheters, respectively. the postoperative pain at rest, pain with movement, the number of rescue analgesics and adverse effects were evaluated for 48 h after caesarean delivery.


Eligibility criteria:
inclusion criteria: * nulliparous parturients who scheduled for elective caesarean delivery under spinal-epidural anaesthesia; * parturients who had requested postoperative analgesia; * parturients aged between 20-35 years old; * parturients who had a full-term pregnancy; * parturients who were identified as having a singleton pregnancy; and * parturients who were categorised as having an american society of anaesthesiologists (asa) physical status exclusion criteria: * parturients with severe internal, surgical or obstetric comorbidities (including spinal deformities, hypertension, placental abruption, cholestasis in pregnancy, asthma, heart disease and abnormal coagulation parameters) * parturients with a known allergy to the drugs used in this study * parturients with severe mental illness who could not comply with doctors' instructions * parturients with chronic pain syndrome, which is defined as pain that persists for a period longer than 3 months
the course of hip flexion weakness following llif or alif

Conditions: Degenerative Disc Disease; Herniated Nucleus Pulposus; Spondylolisthesis

Summary: the purpose of this study is to assess the course of hip weakness after llif or alif procedures. these outcomes include measures of hip strength using a dynamometer, which is a device used to measure muscle strength. while it is known that people experience temporary hip and leg weakness after an llif or alif, the exact timing of when hip and leg strength is regained after an llif or alif is not known.


Eligibility criteria:
inclusion criteria: * 1-, 2-, or 3-level l2l3, l3l4, or l4l5 llif or alif for degenerative pathology including radiculopathy, neurogenic claudication, intervertebral disc disease, facet joint disease, degenerative spondylolisthesis, degenerative myelopathy degenerative kyphosis, and scoliosis * back and/or leg pain * failed at least 6 months of conservative treatment exclusion criteria: * older than 65 years of age * prior spinal fusion surgery * greater than grade 2 spondylolisthesis * greater than 10° scoliosis * history of spinal infection
young adult naturalistic alcohol study (yanas) using smartphone technology in a simulated laboratory environment

Conditions: Alcohol Use; Alcohol Drinking; Drinking Behavior

Summary: it is important to explore use of technology to reduce drinking. the purpose of this research study is to compare different types of mobile technology for their effects on alcohol drinking and ratings of usability among young adults.this study will be conducted in four phases: a web-based screening assessment; brief appointment on the day of the alcohol drinking session; alcohol drinking session; and a follow-up appointment. participation in this study will last approximately two months.


Eligibility criteria:
inclusion criteria: * be able to read english and complete assessments * drink alcohol regularly exclusion criteria: * test positive on a urine test for use of certain illegal drugs * undergraduate student enrolled in the university of florida * graduate students from the college of health and human performance at the university of florida * pregnant, or breast feeding

Keywords: brief intervention web-based interventions harm reduction young adult college student
myofascial release technique vs posterior-anterior glide on non-specific low back pain

Conditions: Low Back Pain

Summary: the objective of this randomized control trial is to determine the effectiveness of myofascial release in patients with nonspecific low back pain to improve pain, disability, and quality of life this study is being conducted at the outpatient physiotherapy department of sindh institute of physical medicine and rehabilitation, karachi (former institute of dow university of health sciences) and musculoskeletal outpatient department of dr. ruth k. m. pfau, civil hospital karachi among 72 patients with nonspecific back pain on the basis of non-probability purposive sample technique with screening for study criteria through a consultant physician (blinded). after taking informed consent, all participants will be randomly allocated into two groups through a second researcher who is not involved in screening, baseline assessment, and providing intervention. group 1 will receive myofascial release with generalized low back stretching and thermotherapy and group 2 will receive posterior-anterior glide with generalized low back stretching and thermotherapy. a total of 18 sessions will be provided. outcomes will be assessed at baseline, at the last session, and after 12 weeks of follow-up.


Eligibility criteria:
inclusion criteria: nonspecific low back pain \> 3 months 8 and 45 years of age ipmr and civil musculoskeletal outpatient department patients without referred leg pain exclusion criteria: any trauma, spinal infection or tumor, spinal fracture, previous spinal surgery, systemic disease, fibromyalgia, cauda equine syndrome, serious chronic disease, specific neurological disease (stroke, ms, and parkinson's disease) uncontrolled diabetes or hypertension pregnant females spondylolisthesis, spinal stenosis, spondylolysis, ankylosing spondylitis, structural deformity, congenital deformation, disc disease, sacroiliitis, severe structural deformity, scoliosis, active structural deficit, and severe postural abnormality acute coronary disease asthmatic patients any contraindication prescribed for myofascial treatment

Keywords: chronic pain disabled persons myofascial release low back pain back pain exercise therapy quality of life
a prospective study of spasticity in individuals with multiple sclerosis

Conditions: Spasticity

Summary: this study is expected to contribute to the body of knowledge on the benefits of individuals with ms taking glatiramer acetate (copaxone®). if patients have less spasticity when taking glatiramer acetate (copaxone®), they may be more likely to have an improved quality of life. the hypotheses for this study are: 1. study participants who transition from interferon therapy to glatiramer acetate (copaxone®) for a six month period will have a decrease in spasticity. 2. study participants who transition from interferon therapy to glatiramer acetate (copaxone®) for a six month period will have a change in perceptions of the impact of spasticity on their lives.

the purpose of this study is to determine if there is a change in spasticity and perceptions of the impact of spasticity in individuals with multiple sclerosis who transition from interferon to glatiramer acetate (copaxone®).• * potential participants meeting the criteria will be identified by shared solutions and informed of the study. interested individuals will contact the investigator either by email or telephone. enrollment will continue until there are 110 participants starting glatiramer acetate (copaxone®). * potential participants will be informed of the details of the study, eligibility will be confirmed, and participant's questions answered. * the two study instruments and the sociodemographic questionnaire will be emailed or mailed via ups along with an information letter. may be returned either via email, fax or ups mail. * at month 6 for each participant, the study instruments and sociodemographic questionnaire will be sent a second time and returned to the investigator.

Eligibility criteria:
inclusion criteria: * stopped interferon (beta-1a or beta-1b) within the past 30 days * about to start or started glatiramer acetate (copaxone®) within the past 21 days. * at least 18 years of age * has spasticity at the beginning of the study * able to ambulate with unilateral support or without support * understands, speaks and reads english exclusion criteria: * severe gait disability or total gait disability